BENITIONSClinical Trial Intelligence

Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines

Phase 4 Terminated NCT02090998

ConditionTransformed Migraine, Chronic Daily Headache
PhasePhase 4
SponsorRutgers, The State University of New Jersey
StatusTerminated
Enrollment10 participants
InterventionsSPG Block with 5% Lidocaine gel, Amitriptyline
Start dateMay, 2014
Completion dateMar 16, 2020
Results postedDec 29, 2021

Summary

This study will compare a local anesthetic technique that has been used to treat subjects suffering from transformed migraines (chronic migraines) versus medical management with traditional antidepressant Amitriptyline / Elavil. Subjects will be randomized into one of two treatment groups to compare the safety and efficacy of the therapies. Subjects will recieve either sphenopalatine ganglion nerve block with 5% lidocaine gel into the nasopharynx or medical management with traditional antidepressants, Elavil, to produce a reduction in the frequency and severity of the headache. We propose that there will be a difference in the outcomes when comparing the two methods of treating transformed migraines and that one research arm will result in more patient satisfaction and greater efficacy in the treatment of subjects

Number of Daily Headaches

Study Day 1 through Study Day 30 · Number of Daily Headaches

Amitriptyline / Elavil20.5 ± 0.5 Number of Daily Headaches
SPG Nerve Block With Lidocaine 5% Gel13.4 ± 10.4 Number of Daily Headaches

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.